177 related articles for article (PubMed ID: 25081726)
1. A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Wu XY; Huang XE; Cao J; Shi L; Xu X; Qian ZY
Asian Pac J Cancer Prev; 2014; 15(14):5941-4. PubMed ID: 25081726
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Wu XY; Huang XE; You SX; Lu YY; Cao J; Liu J
Asian Pac J Cancer Prev; 2013; 14(3):2019-22. PubMed ID: 23679311
[TBL] [Abstract][Full Text] [Related]
3. The role of pemetrexed in the treatment of colorectal cancer.
Hochster H
Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812
[TBL] [Abstract][Full Text] [Related]
4. Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
Wei GL; Huang XE; Huo JG; Wang XN; Tang JH
Asian Pac J Cancer Prev; 2013; 14(5):2703-6. PubMed ID: 23803018
[TBL] [Abstract][Full Text] [Related]
5. Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC).
Liu J; Huang XE; Feng JF
Asian Pac J Cancer Prev; 2014; 15(16):6587-90. PubMed ID: 25169492
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed in the treatment of non-small cell lung cancer.
Shepherd FA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed in patients with gastrointestinal carcinoma.
de Gramont A; Kindler HL
Semin Oncol; 2002 Apr; 29(2 Suppl 5):42-9. PubMed ID: 12023792
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced pancreatic cancer.
Chua YJ; Cunningham D
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):327-48. PubMed ID: 16549331
[TBL] [Abstract][Full Text] [Related]
13. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Misset JL
Semin Oncol; 2002 Feb; 29(1 Suppl 3):36-9. PubMed ID: 11894006
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed in advanced colorectal cancer.
Louvet C; de Gramont A
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):56-62. PubMed ID: 15655939
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
[TBL] [Abstract][Full Text] [Related]
17. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Ghezzi V; Frontini L; Giani L; Vaghi M; Ardizzoia A; Gardani GS
Int J Biol Markers; 2004; 19(2):135-40. PubMed ID: 15255546
[TBL] [Abstract][Full Text] [Related]
20. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
